Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.3%

Eli Lilly and Company (NYSE:LLY) shares were down 1.3% during mid-day trading on Thursday . The company traded as low as $718.30 and last traded at $722.73. Approximately 958,152 shares traded hands during trading, a decline of 68% from the average daily volume of 3,012,311 shares. The stock had previously closed at $732.20.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LLY. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Trading Down 1.0 %

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $688.74 billion, a PE ratio of 124.61, a P/E/G ratio of 1.63 and a beta of 0.34. The business’s fifty day moving average price is $763.40 and its 200 day moving average price is $664.52.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the business earned $2.09 earnings per share. The company’s revenue was up 28.1% compared to the same quarter last year. As a group, analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently modified their holdings of LLY. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the third quarter worth approximately $27,000. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $29,000. Core Wealth Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.